Calcium/calmodulin-dependent protein kinase II mediates hippocampal glutamatergic plasticity during benzodiazepine withdrawal.
Benzodiazepine withdrawal anxiety is associated with potentiation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate receptor (AMPAR) currents in hippocampal CA1 pyramidal neurons attributable to increased synaptic incorporation of GluA1-containing AMPARs. The contribution of calcium/calmodulin-dependent protein kinase II (CaMKII) to enhanced glutamatergic synaptic strength during withdrawal from 1-week oral flurazepam (FZP) administration was further examined in hippocampal slices. As earlier reported, AMPAR-mediated miniature excitatory postsynaptic current (mEPSC) amplitude increased in CA1 neurons from 1- and 2-day FZP-withdrawn rats, along with increased single-channel conductance in neurons from 2-day rats, estimated by non-stationary noise analysis. Input-output curve slope was increased without a change in paired-pulse facilitation, suggesting increased AMPAR postsynaptic efficacy rather than altered glutamate release. The increased mEPSC amplitude and AMPAR conductance were related to CaMKII activity, as intracellular inclusion of CaMKIINtide or autocamtide-2-related inhibitory peptide, but not scrambled peptide, prevented both AMPAR amplitude and conductance changes. mEPSC inhibition by 1-naphthyl acetyl spermine and the negative shift in rectification index at both withdrawal time points were consistent with functional incorporation of GluA2-lacking AMPARs. GluA1 but not GluA2 or GluA3 levels were increased in immunoblots of postsynaptic density (PSD)-enriched subcellular fractions of CA1 minislices from 1-day FZP-withdrawn rats, when mEPSC amplitude, but not conductance, was increased. Both GluA1 expression levels and CaMKII alpha-mediated GluA1 Ser(831) phosphorylation were increased in PSD-subfractions from 2-day FZP-withdrawn rats. As phospho-Thr(286)CaMKII alpha was unchanged, CaMKII alpha may be activated through an alternative signaling pathway. Synaptic insertion and subsequent CaMKII alpha-mediated Ser(831) phosphorylation of GluA1 homomers contribute to benzodiazepine withdrawal-induced AMPAR potentiation and may represent an important hippocampal pathway mediating both drug-induced and activity-dependent plasticity.
Shen
Guofu
G
Department of Physiology and Pharmacology, University of Toledo College of Medicine, Health Science Campus, Toledo, OH 43614, USA.
Van Sickle
Bradley J
BJ
Tietz
Elizabeth I
EI
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001569:Benzodiazepines / Q000008:administration & dosage*; D055592:Biophysical Phenomena / Q000187:drug effects; D001703:Biophysics; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000378:metabolism*; D004195:Disease Models, Animal; D004347:Drug Interactions; D004558:Electric Stimulation; D004791:Enzyme Inhibitors / Q000494:pharmacology; D018683:Excitatory Amino Acid Agents / Q000494:pharmacology; D005479:Flurazepam / Q000494:pharmacology; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D018698:Glutamic Acid / Q000378:metabolism*; D006624:Hippocampus / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D009473:Neuronal Plasticity / Q000187:drug effects*; D018408:Patch-Clamp Techniques; D017966:Pyramidal Cells / Q000187:drug effects* / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D017470:Receptors, Glutamate / Q000378:metabolism; D013347:Subcellular Fractions / Q000187:drug effects / Q000378:metabolism; D013375:Substance Withdrawal Syndrome / Q000473:pathology / Q000503:physiopathology; D013997:Time Factors
D004791:Enzyme Inhibitors; D018683:Excitatory Amino Acid Agents; D006993:Hypnotics and Sedatives; D017470:Receptors, Glutamate; D001569:Benzodiazepines; D018698:Glutamic Acid; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2; D005479:Flurazepam
Nat Neurosci. 1998 Sep;1(5):378-83
10196527
Curr Opin Pharmacol. 2005 Feb;5(1):47-52
15661625
Trends Neurosci. 2003 Jan;26(1):9-11
12495855
Biochem Soc Trans. 2009 Dec;37(Pt 6):1394-8
19909283
Science. 1991 May 10;252(5007):851-3
1709304
Nat Rev Neurosci. 2004 Dec;5(12):952-62
15550950
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3269-74
10077673
Nat Neurosci. 2006 May;9(5):602-4
16582904
Neuropsychopharmacology. 2004 Nov;29(11):1994-2006
15266351
Nat Neurosci. 2008 Mar;11(3):344-53
18278040
Nat Neurosci. 2007 Apr;10(4):469-77
17351635
J Neurosci. 2006 Jan 25;26(4):1164-74
16436603
J Neurosci. 2008 Jun 4;28(23):6000-9
18524905
Nat Neurosci. 2003 Feb;6(2):136-43
12536214
Philos Trans R Soc Lond B Biol Sci. 2003 Apr 29;358(1432):721-6
12740118
J Neurochem. 2007 Dec;103(6):2518-28
17949410
Synapse. 2009 Aug;63(8):690-7
19360908
Nat Rev Neurosci. 2007 Feb;8(2):101-13
17237803
Synapse. 2009 Mar;63(3):224-35
19084907
Exp Neurol. 2008 Apr;210(2):750-61
18294632
Eur J Neurosci. 1994 Jul 1;6(7):1080-8
7524964
Science. 2000 Mar 24;287(5461):2262-7
10731148
Pharmacology. 1997 Nov;55(5):217-27
9399331
Nat Rev Neurosci. 2002 Mar;3(3):175-90
11994750
J Physiol. 1995 Jan 15;482 ( Pt 2):325-52
7536248
Synapse. 2005 Oct;58(1):1-12
16037950
BMC Neurosci. 2004 Nov 11;5:44
15538948
Neuron. 1998 Sep;21(3):593-606
9768845
J Neurosci. 2005 Apr 6;25(14):3674-9
15814798
J Neurochem. 2009 Jul;110(1):363-77
19457111
Neuron. 2009 Apr 30;62(2):254-68
19409270
J Neurophysiol. 2010 Jan;103(1):479-89
19906877
J Biol Chem. 1997 Dec 19;272(51):32528-33
9405465
Neuropharmacology. 2002 Sep;43(4):595-606
12367605
Science. 1999 Jun 11;284(5421):1811-6
10364548
J Neurosci. 2007 May 9;27(19):5190-9
17494705
J Biol Chem. 1997 Dec 26;272(52):32727-30
9407043
J Neurosci. 2007 Apr 25;27(17):4598-602
17460072
Synapse. 1995 Dec;21(4):289-98
8869159
J Neurosci. 2003 Oct 15;23(28):9367-73
14561864
Science. 1997 Jun 27;276(5321):2042-5
9197267
Nature. 2001 Jun 14;411(6839):801-5
11459059
J Neurosci. 1996 Mar 15;16(6):1982-9
8604042
Behav Pharmacol. 2007 Sep;18(5-6):447-60
17762513
J Comp Neurol. 2003 Jul 14;462(1):15-28
12761821
J Neurosci. 2005 Oct 5;25(40):9144-51
16207873
J Neurosci. 2002 Jun 1;22(11):4406-11
12040047
Neuropharmacology. 2009 Jan;56(1):2-5
18655795
Neuropharmacology. 2002 Jul;43(1):11-27
12213255
Biochem Biophys Res Commun. 2006 Jul 14;345(4):1606-10
16730662
J Physiol. 2006 Jun 1;573(Pt 2):371-94
16527860
Psychopharmacology (Berl). 1998 Apr;136(3):308-10
9566818
Nat Neurosci. 2005 Jul;8(7):853-4
15924137
J Neurosci. 2010 Jan 20;30(3):939-49
20089902
J Pharmacol Exp Ther. 2007 Aug;322(2):569-81
17510319
Nature. 2003 Jan 2;421(6918):70-5
12511956
J Neurosci. 1996 Jan;16(1):274-82
8613793
J Pharmacol Exp Ther. 2008 Dec;327(3):872-83
18812492
Biochem Biophys Res Commun. 1995 Jul 26;212(3):806-12
7626114
Proc Natl Acad Sci U S A. 2001 Mar 13;98(6):3483-8
11248104
Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11175-9
7479960
J Pharmacol Exp Ther. 1996 Aug;278(2):669-78
8768718
Neuropharmacology. 2004;47 Suppl 1:61-79
15464126
Neuron. 2004 Sep 30;44(1):75-91
15450161
Nat Rev Neurosci. 2007 Nov;8(11):844-58
17948030
Neuroscience. 2009 Mar 3;159(1):414-26
19105975
J Neurosci. 1997 Jan 1;17(1):58-69
8987736
Nature. 1998 Jun 25;393(6687):793-7
9655394
Curr Pharm Des. 2002;8(1):5-21
11812247
J Clin Psychiatry. 2005;66 Suppl 9:31-41
16336040
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20033-8
19892736
Nature. 1997 Dec 11;390(6660):607-11
9403689
Synapse. 1999 Mar 15;31(4):263-77
10051107
Nat Neurosci. 2000 Nov;3(11):1098-106
11036266
Pharmacol Ther. 2003 May;98(2):171-95
12725868
J Comp Neurol. 2010 Nov 1;518(21):4311-28
20853509
Neuron. 1995 Aug;15(2):443-52
7646896
J Neurochem. 1996 Jan;66(1):1-5
8522940
J Comp Neurol. 2008 Dec 20;511(6):832-46
18924138
Proc Natl Acad Sci U S A. 1985 May;82(9):3035-9
2859595